Aflibercept (AF) for age-related macular degeneration (ARMD): four-year outcomes of a ‘’treat-and-extend’ (T&E) regimen with exit-strategy
Reviewed by Jonathan Chan

This is a retrospective observational study of 82 patients, between 2014 to 2016 from Switzerland of treatment-naive patients with nARMD, treated with AF, with specific T&E protocol without a loading phase and predefined exit criteria and patients were observed three monthly. Best-corrected visual acuity (BCVA) increased from (mean) 51.9 ETDRS letters at baseline to 63.7 at one year, 61.7 at two years, 61.4 at three years and 58.5 at four years (p=0.22). Central field thickness decreased significantly from (mean) 387.5um at baseline, to 289um at four years (p<0.00001). Twenty-eight (35%) patients reached exit strategy and on three monthly observation only. The authors concluded that their cohort on functional outcome is comparable to large studies.

Aflibercept for age-related macular degeneration: 4-year outcomes of a ‘treat-and-extend’ regimen with exit-strategy.
Jaggi D, Nagamany T, Ebneter A, et al.
BRITISH JOURNAL OF OPHTHALMOLOGY
2022;106(2):246-50.